Agilent Technologies (NYSE:A) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Agilent Technologies (NYSE:A) issued its quarterly earnings results on Wednesday. The medical research company reported $1.49 EPS for the quarter, beating the consensus estimate of $1.40 by $0.09, FiscalAI reports. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. Agilent Technologies updated its FY 2026 guidance to 6.000-6.100 EPS and its Q3 2026 guidance to 1.480-1.500 EPS.

Agilent Technologies Stock Up 0.6%

Shares of A traded up $0.74 during mid-day trading on Wednesday, hitting $115.82. The company’s stock had a trading volume of 2,911,282 shares, compared to its average volume of 2,192,228. The company’s 50-day moving average is $114.91 and its 200-day moving average is $129.01. Agilent Technologies has a 52-week low of $108.35 and a 52-week high of $160.27. The firm has a market capitalization of $32.73 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 2.42 and a beta of 1.22. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Tuesday, June 30th will be given a $0.255 dividend. This represents a $1.02 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, June 30th. Agilent Technologies’s dividend payout ratio is presently 22.52%.

Wall Street Analysts Forecast Growth

A has been the subject of several research reports. Barclays lowered their price objective on shares of Agilent Technologies from $150.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Royal Bank Of Canada initiated coverage on shares of Agilent Technologies in a research report on Wednesday. They issued an “outperform” rating and a $153.00 price objective for the company. Wall Street Zen cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Robert W. Baird boosted their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Morgan Stanley lowered their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $162.40.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent raised its FY 2026 outlook, guiding for EPS of $6.00-$6.10 and revenue of $7.4 billion-$7.5 billion, both in line to slightly above Wall Street expectations. The company also guided Q3 EPS to $1.48-$1.50 on revenue of $1.8 billion-$1.9 billion, signaling stable demand and execution.
• Positive Sentiment: Royal Bank of Canada initiated/started coverage with an Outperform rating and a $153 price target, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Robert W. Baird also raised its price target to $156 and reiterated an Outperform rating, reinforcing analyst confidence ahead of the next earnings cycle. Benzinga
• Neutral Sentiment: Recent product and conference announcements, including new GC systems, a MAM solution for biopharma quality control, and cancer research showcases, highlight ongoing innovation but are less likely to move the stock immediately.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in shares of Agilent Technologies by 1.9% in the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock worth $1,725,611,000 after purchasing an additional 241,029 shares during the period. Morgan Stanley lifted its position in shares of Agilent Technologies by 15.9% in the 4th quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock worth $686,049,000 after purchasing an additional 692,202 shares during the period. Invesco Ltd. lifted its position in shares of Agilent Technologies by 32.0% in the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock worth $352,519,000 after purchasing an additional 627,804 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Agilent Technologies by 132.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock worth $277,807,000 after purchasing an additional 1,340,161 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Agilent Technologies by 424.1% in the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after purchasing an additional 1,652,244 shares during the period. Hedge funds and other institutional investors own 87.41% of the company’s stock.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.